Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Bullboard Posts
Comment by Blackgoldexperton Jan 06, 2018 7:59pm
375 Views
Post# 27298797

RE:Good news for ISOL...

RE:Good news for ISOL... Exclusive article by Alan Brochstein, CFA Health Canada released monthly data yesterday on its medical cannabis program, Access to Cannabis for Medical Purposes Regulations (ACMPR), which was implemented as MMPR in April 2016. The number of patients as of September 30, 2017 increased to 235,621 from 201,398 at the end of June and 98,460 as of September 2016, representing quarterly growth of 17% and annual growth of 139%: While the growth was strong, it was the slowest annual growth since the program launched, reflecting the maturation of the program and perhaps some hesitancy of potential patients to register with legalization approaching: Health Canada began releasing data by province beginning in the quarter ending June 30th. Ontario, which showed 12% growth from the prior quarter, had 96,390 patients, while Alberta, which grew 23% from the prior quarter, had 91,150. These two provinces represent almost 80% of the entire patient base as of September 30th: The data continued to show strong demand for oils relative to dried flower. During the quarter, the LPs shipped 5.905mm grams compared to 5.895mm grams in the prior quarter, representing growth of just 0.2% and 23.7% from a year ago. Oil sales, expressed in weight, were 7.669mm grams, up 23.8% from the prior quarter and 216.9% from a year ago
Bullboard Posts